Early quality of life outcomes in patients with prostate cancer managed by high‐dose‐rate brachytherapy as monotherapy

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International journal of urology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1442-2042.2012.03125.xPMID 22905941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.

  2012cited by this paper
• Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions.

  2011cited by this paper
• High-Dose-Rate Prostate Brachytherapy: An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer

  2010cited by this paper
• Clinical results of iridium-192 high dose rate brachytherapy with external beam radiotherapy.

  2010cited by this paper
• Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.

  2010cited by this paper
• Health-Related Quality of Life after Radical Prostatectomy and Low-Dose-Rate Brachytherapy for Localized Prostate Cancer

  2009cited by this paper
• Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.

  2009cited by this paper
• Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.

  2009cited by this paper
• Quality of life and satisfaction with outcome among prostate-cancer survivors.

  2008cited by this paper
• Quality of life and satisfaction with outcome among prostate-cancer survivors.

  2008cited by this paper
• The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.

  2007cited by this paper
• High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial.

  2007cited by this paper
• Percentage of positive biopsy cores, preoperative prostate‐specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi‐institutional outcome study in Japan

  2006cited by this paper
• A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.

  2006cited by this paper
• Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

  2006cited by this paper
• Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients.

  2006cited by this paper
• Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study.

  2006cited by this paper
• Erectile function after prostate brachytherapy.

  2005cited by this paper
• Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.

  2005cited by this paper
• 3-D Conformal HDR Brachytherapy as Monotherapy for Localized Prostate Cancer

  2004cited by this paper
• High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.

  2003cited by this paper
• Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.

  2001cited by this paper
• A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy.

  2001cited by this paper
• Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer.

  2001cited by this paper
• High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.

  2000cited by this paper
• Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer

  2000cited by this paper
• Fractionation and protraction for radiotherapy of prostate carcinoma.

  1999cited by this paper
• External beam radiation monotherapy for prostate cancer

  1999cited by this paper
• Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

  1998cited by this paper
• The linear-quadratic formula and progress in fractionated radiotherapy.

  1989cited by this paper

• AAPM Task Group Report 267: A joint AAPM GEC‐ESTRO report on biophysical models and tools for the planning and evaluation of brachytherapy

  2024cites this paper
• High-dose-rate Brachytherapy Monotherapy in Patients With Localised Prostate Cancer: Dose Modelling and Optimisation Using Computer Algorithms.

  2024cites this paper
• High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome

  2021cites this paper
• High-dose-rate brachytherapy as monotherapy for prostate cancer: The impact of cellular repair and source decay.

  2019cites this paper
• A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

  2019cites this paper
• Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis.

  2018influential citation
• High dose rate brachytherapy as monotherapy for localised prostate cancer.

  2017cites this paper
• Brachytherapy guideline in prostate cancer (high and low dose rate).

  2017cites this paper
• High Dose Rate Brachytherapy as Monotherapy for Localised Prostate Cancer: Review of the Current Status.

  2017cites this paper
• High-dose rate brachytherapy as monotherapy in prostate cancer: A systematic review of its safety and efficacy.

  2017cites this paper
• Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer.

  2017cites this paper
• Braquiterapia de alta tasa de dosis como monoterapia en cáncer de próstata: una revisión sistemática sobre eficacia y seguridad

  2017cites this paper
• Prostate: High-Dose Rate Brachytherapy in the Treatment of Clinically Organ-Confined Prostate Cancer

  2016cites this paper
• Governance and functionality of community water schemes in rural Ethiopia

  2015cites this paper
• Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature.

  2015cites this paper
• State of the Art Review High-dose-rate brachytherapy as monotherapy for prostate cancer

  2014cites this paper
• High-Dose-Rate Brachytherapy in the Treatment of Clinically Localized Prostate Cancer

  2014cites this paper
• High-dose-rate brachytherapy as monotherapy for prostate cancer.

  2014cites this paper
• High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer

  2014cites this paper
• A critical ACR appropriateness Criteria omission.

  2014cites this paper
• Response to Drs Rogers, Hayes, and Demanes.

  2014cites this paper
• A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

  2013cites this paper
• The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer

  2013cites this paper